Swapan K. Chowdhury - Publications, H-index & Citations

Swapan K. Chowdhury

Takeda Pharmaceutical Company Ltd

39H指数

124论文数

4.9K被引数

收录论文 30

发表时间

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial Efimosfermin alfa (BOS-580)，一种长效FGF21类似物，在具有表型代谢功能障碍相关脂肪性肝炎的受试者中：一项多中心、随机、双盲、安慰剂对照的2a期试验

The Lancet Gastroenterology & Hepatology

IF0

2025-06-06

PREAI

Rohit Loomba; Kris V Kowdley; Jose Rodriguez; Nomita J Kim; Alina Maria Alvarez; Linda Morrow; Brenda Jeglinski; Alicia Clawson; Swapan Chowdhury; Gerard Bain; Tatjana Odrljin

Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-11-12

OAAI

Yin, Wei; Ballard, T. Eric; Zhu, Sean Xiaochun; Hsiao, Samuel; Chen, Hao; Li, Yuexian; Chowdhury, Swapan K.; Stevenson, Annette; Hui, Tom; Hunt, Allen; Asgharnejad, Mahnaz; Han, Steve

Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)

AAPS JOURNAL

IF3.7

2022-09-19

OAAI

Sandoval, Philip; Chuang, Bei-Ching; Fallon, John K.; Smith, Philip C.; Chowdhury, Swapan K.; Griffin, Robert J.; Xia, Cindy Q.; Iwasaki, Shinji; Chothe, Paresh P.

Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study RNA病毒药物对SARS-CoV-2蛋白的抑制作用: 一项广泛的研究

JOURNAL OF MOLECULAR STRUCTURE

IF4.7

2021-06-01

OAAI

Mandal, Manab; Chowdhury, Swapan Kumar; Khan, Abdul Ashik; Baildya, Nabajyoti; Dutta, Tanmoy; Misra, Debabrata; Ghosh, Narendra Nath

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

INVESTIGATIONAL NEW DRUGS

IF2.7

2020-10-22

OAAI

Zhou, Xiaofei; Sedarati, Farhad; Faller, Douglas V.; Zhao, Dan; Faessel, Helene M.; Chowdhury, Swapan; Bolleddula, Jayaprakasam; Li, Yuexian; Venkatakrishnan, Karthik; Papai, Zsuzsanna

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

INVESTIGATIONAL NEW DRUGS

IF2.7

2018-11-06

PREAI

Zhou, Xiaofei; Pusalkar, Sandeepraj; Chowdhury, Swapan K.; Searle, Shawn; Li, Yuexian; Ullmann, Claudio Dansky; Venkatakrishnan, Karthik

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

ESMO OPEN

IF8.3

2018-01-01

OAAI

Moore, Kathleen N.; Bauer, Todd M.; Falchook, Gerald S.; Chowdhury, Swapan; Patel, Chirag; Neuwirth, Rachel; Enke, Aaron; Zohren, Fabian; Patel, Manish R.

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

INVESTIGATIONAL NEW DRUGS

IF2.7

2017-09-21

OAAI

Gupta, Neeraj; Zhang, Steven; Pusalkar, Sandeepraj; Plesescu, Mihaela; Chowdhury, Swapan; Hanley, Michael J.; Wang, Bingxia; Xia, Cindy; Zhang, Xiaoquan; Venkatakrishnan, Karthik; Shepard, Dale R.

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury Fasiglifam (TAK-875) 改变大鼠和狗的胆汁酸稳态: 药物引起的肝损伤的潜在原因

TOXICOLOGICAL SCIENCES

IF4.1

2017-01-20

OAAI

Wolenski, Francis S.; Zhu, Andy Z. X.; Johnson, Mike; Yu, Shaoxia; Moriya, Yuu; Ebihara, Takuya; Csizmadia, Vilmos; Grieves, Jessica; Paton, Martin; Liao, Mingxiang; Gemski, Christopher; Pan, Liping; Vakilynejad, Majid; Dragan, Yvonne P.; Chowdhury, Swapan K.; Kirby, Patrick J.

A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

EUROPEAN JOURNAL OF CANCER

IF7.1

2016-12-01

PREAI

Chowdhury, S.; Burris, H. A.; Patel, M.; Infante, J. R.; Jones, S. F.; Voskoboynik, M.; Parry, K.; Elvin, R.; Coleman, T.; Gardner, H.; Lyne, P. D.; Arkenau, H. T.

Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes

DRUG METABOLISM REVIEWS

IF3.8

2015-09-22

PREAI

Bolleddula, Jayaprakasam; Chowdhury, Swapan K.

Combination schedule optimization through preclinical PK-efficacy modeling of an investigational novel-novel combination: A case study of MLN0128 an mTORC1/2 inhibitor with MLN1117 a PI3Kα isoform selective inhibitor.

MOLECULAR CANCER THERAPEUTICS

IF5.5

2013-11-01

PREAI

Zopf, Christopher; Patel, Mayank; Kadakia, Ekta; Fabry, Robyn; Chakravarty, Arijit; Chowdhury, Swapan; Wu, Jing-Tao; Shyu, Wen Chyi; Manfredi, Mark; Zohren, Fabian; Patel, Chirag; Kuida, Keisuke; Iartchouk, Natasha; Brake, Rachael; Mettetal, Jerome

Precision and Accuracy in the Quantitative Analysis of Biological Samples by Accelerator Mass Spectrometry: Application in Microdose Absolute Bioavailability Studies

ANALYTICAL CHEMISTRY

IF6.7

2011-06-20

PREAI

Gao, Lan; Li, Jing; Kasserra, Claudia; Song, Qi; Aromand, Ali; Hesk, David; Chowdhury, Swapan K.

Analytical Strategies for Assessment of Human Metabolites in Preclinical Safety Testing

ANALYTICAL CHEMISTRY

IF6.7

2011-04-20

PREAI

Ma, Shuguang; Chowdhury, Swapan K.